Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,469 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $253.74 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The stock has a market cap of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39. The business has a 50-day simple moving average of $272.32 and a 200-day simple moving average of $240.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the company posted $1.15 EPS. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Plato Investment Management Ltd increased its holdings in Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 4,346 shares in the last quarter. Diversified Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $1,210,000. Los Angeles Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Breakwater Capital Group acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter worth about $249,000. Finally, Sanctuary Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter worth approximately $578,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ALNY has been the subject of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. TD Cowen upped their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Finally, The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.